Clinical Trials Results
|
Results for the search you initiated will be displayed below.
-
Click here for details...
This trial studies how well two surgical procedures (bilateral salpingectomy and bilateral
salpingo-oophorectomy) work in reducing the risk of ovarian cancer for women with BRCA1
mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and
bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and
ovaries. This study may help doctors determine if the two surgical procedures are nearly the
same for ovarian cancer risk reduction for women with BRCA1 mutations.
-
Click here for details...
This randomized phase III trial studies radiation therapy and cisplatin with triapine to see
how well they work compared to the standard radiation therapy and cisplatin alone in treating
patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA
vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink
tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Triapine may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. It is not yet known whether radiation therapy and
cisplatin are more effective with triapine in treating cervical or vaginal cancer.
-
Click here for details...
This phase II trial studies how well olaparib and cediranib maleate work in treating patients
with endometrial cancer that has come back (recurrent), does not respond to treatment
(refractory), or has spread to other places in the body (metastatic). Olaparib and cediranib
maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth.
-
Click here for details...
This phase II trial studies how well tazemetostat works in treating patients with ovarian,
primary peritoneal, or endometrial cancer that has come back. Drugs used in chemotherapy,
such as tazemetostat, work in different ways to stop the growth of tumor cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading.
-
Click here for details...
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and
carboplatin, works compared with paclitaxel and carboplatin alone in treating patients with
endometrial cancer that is stage III or IV, or has come back (recurrent). Immunotherapy with
monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and
carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type
of cancer. This study aims to assess if adding immunotherapy to these drugs is better or
worse than the usual approach for treatment of this cancer.
-
Click here for details...
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin
works in treating patients with stage II-IV low-grade serous carcinoma of the ovary or
peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the
body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used
in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. It is not yet known whether giving letrozole alone or in
combination with paclitaxel and carboplatin works better in treating patients with low-grade
serous carcinoma of the ovary or peritoneum compared to paclitaxel and carboplatin without
letrozole.
-
Click here for details...
This phase III trial compares whether the addition of pembrolizumab to radiation therapy is
more effective than radiation therapy alone in reducing the risk of cancer coming back
(recurrence) in patients with newly diagnosed stage I-II endometrial cancer. Immunotherapy
with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack
the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation
therapy uses high energy x-rays to kill tumor cells and shrink tumors. The addition of
pembrolizumab to radiation treatment may be more effective than radiation treatment alone in
reducing cancer recurrence.
-
Click here for details...
This phase II trial studies the possible benefits of treatment with different combinations of
the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with
ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of
improvement with platinum therapy (recurrent platinum resistant). Usual treatment is the type
of treatment most patients with this condition receive if they are not part of a clinical
study. Combination therapies studied in this trial include MEDI4736 (durvalumab) plus
olaparib and cediranib, durvalumab and cediranib, or olaparib and cediranib. Monoclonal
antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumors cells to grow and spread. Olaparib is an inhibitor of
PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged.
Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to
die. PARP inhibitors are a type of targeted therapy. Cediranib may stop the growth of tumor
cells by blocking VEGF (an enzyme). needed for cell growth. Giving different combinations of
durvalumab, olaparib and cediranib may work better in increasing the duration of time that
the cancer does not progress compared to the usual treatment.
|
